Parkinson's Disease - Ongentys Prior Authorization Policy
Defines Cigna's prior authorization requirements for Ongentys (opicapone) when used as adjunctive therapy to levodopa/carbidopa in patients with Parkinson's disease; applies to providers prescribing under Cigna-administered health benefit plans.
No material clinical or coverage changes in this revision.
Coverage Criteria for Ongentys (opicapone)
Initial approval — FDA-approved use
Covered when ALL of the following are met
Approve for 1 year if all criteria are met; Ongentys used as adjunct to carbidopa/levodopa for 'off' episodes.
Prior authorization required; approvals provided for 1 year.
Requests for Ongentys (opicapone) for any indication other than the FDA‑approved use are considered experimental, investigational, or unproven and may be denied. Coverage is limited to the approved indication described in the policy.
Provider Requirements and Prior Authorization
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.